ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma
Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate ran...
Saved in:
Published in | Blood Vol. 110; no. 11; p. 2895 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
16.11.2007
|
Online Access | Get full text |
Cover
Loading…
Abstract | Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate randomized prospective sample trials. However, it is intellectually appealing. Additionally, the use of the ADAMTS 13 level either to predict disease or outcome has not been resolved.
Methods Cryosupernatant plasma (CSP) was compared to solvent detergent treated plasma (SDP) over one cycle (nine days) of plasma exchange (PE) and subsequent procedures as required. Throughout treatment, ADAMTS 13 and protein S levels were followed.
Results At the primary end point of one month, 3 of 35 of the CSP and 1 of 27 of the SDP patients died. The average platelet count was 184 × 109 per litre for CSP and 209 × 109 per litre for SDP. While vWF and FVIII were elevated in all patients at entry, no unusually large vWF multimers were seen at any time. At entry 9 patients had ≤ 0–10% ADAMTS 13 and 14 of 62 had normal levels with the rest in between. At presentation only 9 patients had 100% inhibitor activity with no inhibitor in 18 patients. Of the four patients who died, two who received CSP, had 100% enzyme activity at presentation whereas one had no ADAMTS-13 and another had 10%. All 4 patients died within 10 days. Fifteen patients with less than 10% enzyme activity had >1.5 vWF. However, elevated (>3u/mL) vWF was seen in the presence of normal ADAMTS-13 levels. Six months after remission, and in the presence of a normal platelet count, ADAMTS13 remained low in 5 patients and normal in 15.Protein S levels in 41/62 patients studied showed little variation during therapy with values on day 3 and 5, similar to those seen on entry.
Conclusion In idiopathic TTP, ADAMTS 13 levels do not correlate with disease, and are not predictive of outcome. While protein S levels in the SDP were lower than those found in FFP, this did not appear to have clinical significance. |
---|---|
AbstractList | Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate randomized prospective sample trials. However, it is intellectually appealing. Additionally, the use of the ADAMTS 13 level either to predict disease or outcome has not been resolved.
Methods Cryosupernatant plasma (CSP) was compared to solvent detergent treated plasma (SDP) over one cycle (nine days) of plasma exchange (PE) and subsequent procedures as required. Throughout treatment, ADAMTS 13 and protein S levels were followed.
Results At the primary end point of one month, 3 of 35 of the CSP and 1 of 27 of the SDP patients died. The average platelet count was 184 × 109 per litre for CSP and 209 × 109 per litre for SDP. While vWF and FVIII were elevated in all patients at entry, no unusually large vWF multimers were seen at any time. At entry 9 patients had ≤ 0–10% ADAMTS 13 and 14 of 62 had normal levels with the rest in between. At presentation only 9 patients had 100% inhibitor activity with no inhibitor in 18 patients. Of the four patients who died, two who received CSP, had 100% enzyme activity at presentation whereas one had no ADAMTS-13 and another had 10%. All 4 patients died within 10 days. Fifteen patients with less than 10% enzyme activity had >1.5 vWF. However, elevated (>3u/mL) vWF was seen in the presence of normal ADAMTS-13 levels. Six months after remission, and in the presence of a normal platelet count, ADAMTS13 remained low in 5 patients and normal in 15.Protein S levels in 41/62 patients studied showed little variation during therapy with values on day 3 and 5, similar to those seen on entry.
Conclusion In idiopathic TTP, ADAMTS 13 levels do not correlate with disease, and are not predictive of outcome. While protein S levels in the SDP were lower than those found in FFP, this did not appear to have clinical significance. Abstract Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative solutions such as cryosupernatant plasma, which is deficient in the high molecular weight forms of vWF. has not been proven by appropriate randomized prospective sample trials. However, it is intellectually appealing. Additionally, the use of the ADAMTS 13 level either to predict disease or outcome has not been resolved. Methods Cryosupernatant plasma (CSP) was compared to solvent detergent treated plasma (SDP) over one cycle (nine days) of plasma exchange (PE) and subsequent procedures as required. Throughout treatment, ADAMTS 13 and protein S levels were followed. Results At the primary end point of one month, 3 of 35 of the CSP and 1 of 27 of the SDP patients died. The average platelet count was 184 × 109 per litre for CSP and 209 × 109 per litre for SDP. While vWF and FVIII were elevated in all patients at entry, no unusually large vWF multimers were seen at any time. At entry 9 patients had ≤ 0–10% ADAMTS 13 and 14 of 62 had normal levels with the rest in between. At presentation only 9 patients had 100% inhibitor activity with no inhibitor in 18 patients. Of the four patients who died, two who received CSP, had 100% enzyme activity at presentation whereas one had no ADAMTS-13 and another had 10%. All 4 patients died within 10 days. Fifteen patients with less than 10% enzyme activity had >1.5 vWF. However, elevated (>3u/mL) vWF was seen in the presence of normal ADAMTS-13 levels. Six months after remission, and in the presence of a normal platelet count, ADAMTS13 remained low in 5 patients and normal in 15.Protein S levels in 41/62 patients studied showed little variation during therapy with values on day 3 and 5, similar to those seen on entry. Conclusion In idiopathic TTP, ADAMTS 13 levels do not correlate with disease, and are not predictive of outcome. While protein S levels in the SDP were lower than those found in FFP, this did not appear to have clinical significance. |
Author | Anderson, David Rock, Gail A. Sutton, David Barth, David Foley, Ronan Leblond, Pierre Benny, Barrett Clark, William |
Author_xml | – sequence: 1 givenname: Gail A. surname: Rock fullname: Rock, Gail A. organization: Canadian Apheresis Group, Ottawa, ON, Canada – sequence: 2 givenname: David surname: Anderson fullname: Anderson, David organization: Queen Elizabeth II HSC, Halifax, NS, Canada – sequence: 3 givenname: Barrett surname: Benny fullname: Benny, Barrett organization: Vancouver General Hospital, Vancouver, BC, Canada – sequence: 4 givenname: David surname: Barth fullname: Barth, David organization: Princess Margaret Hospital, Toronto, ON, Canada – sequence: 5 givenname: William surname: Clark fullname: Clark, William organization: London Health Science Center, London, ON, Canada – sequence: 6 givenname: Ronan surname: Foley fullname: Foley, Ronan organization: Henderson General Hospital, Hamilton, ON, Canada – sequence: 7 givenname: David surname: Sutton fullname: Sutton, David organization: Princess Margaret Hospital, Toronto, ON, Canada – sequence: 8 givenname: Pierre surname: Leblond fullname: Leblond, Pierre organization: Hopital de l'Enfant Jesus, Quebec City, QC, Canada |
BookMark | eNqFkNlOAjEUhhuDiYA-g32BwS7M5t0EcElASEBvJ6U9AzVDSzoF5Z18SAvItRdnzfn_5Hwd1DLWAEL3lPQozdjDsrZW9T7oae6xLI9P6Qq1acyyiBBGWqhNCEmifp7SG9Rpmk9CaJ-zuI1-imExWcwjyvEY9lA3eGjxm_V45kBp6fF056XdANYGL9bObpbWa3lp5cHbLZiwmO3cdufEY9BZD-F4fvErHOCJ0MaHAIXVzmmzwrNaNBuBR99yLcwK8Jf2azy39R6Mx0Pw4FbHbuFA-KA6n9-i60rUDdz91S56fxotBi_RePr8OijGkaQkiSMhklRxkfNMZP1UEUpjqpZAmEokYxyqPE6rVKksqShf5pwRSLjq0zhNmBIq512Unn2ls03joCq3Tm-EO5SUlEfo5Ql6eYQe5vLI-5SCsjgrw-ew1-DKRmowMrB0IH2prP7X4xcKT5Cm |
ContentType | Journal Article |
Copyright | 2007 American Society of Hematology |
Copyright_xml | – notice: 2007 American Society of Hematology |
DBID | 6I. AAFTH AAYXX CITATION |
DOI | 10.1182/blood.V110.11.2895.2895 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 2895 |
ExternalDocumentID | 10_1182_blood_V110_11_2895_2895 S0006497119891449 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 9M8 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFFNX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 J5H K-O KQ8 L7B LSO MJL N4W N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 ZGI 0R~ 0SF AALRI AAYXX ADVLN AITUG AKRWK AMRAJ CITATION H13 |
ID | FETCH-LOGICAL-c1065-aa67d3a938a847d01151dbe02d6c223ef957f7dd86f13b9320e63d415762dad93 |
IEDL.DBID | ABVKL |
ISSN | 0006-4971 |
IngestDate | Fri Aug 23 00:41:19 EDT 2024 Fri Feb 23 02:43:52 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
License | This article is made available under the Elsevier license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1065-aa67d3a938a847d01151dbe02d6c223ef957f7dd86f13b9320e63d415762dad93 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497119891449 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_V110_11_2895_2895 elsevier_sciencedirect_doi_10_1182_blood_V110_11_2895_2895 |
PublicationCentury | 2000 |
PublicationDate | 2007-11-16 |
PublicationDateYYYYMMDD | 2007-11-16 |
PublicationDate_xml | – month: 11 year: 2007 text: 2007-11-16 day: 16 |
PublicationDecade | 2000 |
PublicationTitle | Blood |
PublicationYear | 2007 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 1.906931 |
Snippet | Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of alternative... Abstract Introduction The ultimate therapy for TTP is not yet defined. While approximately 85% of patients respond to plasma exchange with FFP, the use of... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 2895 |
Title | ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma |
URI | https://dx.doi.org/10.1182/blood.V110.11.2895.2895 |
Volume | 110 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB5REG0vVbtQQR9oDhW3sHk6CbewC6KFhZV2QdwiO_aqK7EJSrNS-U_9kZ1xElSkSj30YsWRJ4k8jucb-xsPwBfpizhUgo--jF0nTFzpqCgNnVBwmnIVewu7Yzq5Euc34be76G4DRn0sDNMqu7m_ndPtbN3dGXa9OXxYLjnGl8xpGnvM-iG3IH0BWz6hX_o7t7KT24vLp82EMPDbRAbkPLNAR_MiZD207PCjW8_Wj8j5iGzxdyP1h-E5ewtvOsSIWftR72DDlAPYyUryllePeIiWw2kXxwewfdJfvRr1mdwG8HLSbaDvwK9snE3mM8cL8JLpQj9wXOFV1eC05jYNXq8b6gqDyxLn3-tqpSp6bX9ZPDacbYtuTEk_61oek1zF-TJx1j8vqw1O5LLkJQejsQ2DxCmB9JXE059toDHy8i_OqntmW-KYKTkc4oVzhrAk1TbfhZuz0_no3OkSNjgFeZaRI6WIdSDTIJFk9DSjTU8r4_paFARDzCKN4kWsdSIWXqAIObpGBJogBM3IWuo0eA-bZVWaPcAoJeQgImOSQoVKaSXImhdaRGnhalLzPri9hvKH9lyO3PoziZ9bpeasVKrnrE9b7MNxr8n82RDLyXr8S_jD_wh_hNd2SZjZg-ITbDb12nwmLNOog26sHhCa_3rxG9qY8VI |
link.rule.ids | 315,783,787,27581,27936,27937,45675 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdGJ9heEHRMbHzdA-Ita77sNHvL2k2FNaVSs2lvkR27ohJNppBK7H_ij-TOSRBISDzwEtmWL4l8lu939u98jL2XvohCJejqy8h1wrErHcXj0AkFpSlXkbe2J6bpQsxuwk93_G6PTfpYGKJVdmt_u6bb1bprGXWjObrfbCjGF81pHHnE-kG3IH7E9hENRHzA9pOL2-v5r8OEMPDbRAboPJNAR_NCZD2y7PCzW8_Wz9D54PbxdyP1m-G5esaedogRkvannrM9Uw7ZUVKit7x9gA9gOZx2c3zIHl_0pYNJn8ltyJ6k3QH6EfuRTJM0WzleAHOiC32DaQWLqoFlTX0a-LxrcCgMbErIvtTVVlX42b5YPDSUbQsblqifXS3PUa6ifJmw6t-X1AZSuSlpy8FoaMMgYYkgfSvh8nsbaAy0_Qur6iuxLWFKlBwK8YKMICxKtd1fsJury2wyc7qEDU6BniV3pBSRDmQcjCUaPU1o09PKuL4WBcIQs455tI60Hou1FyhEjq4RgUYIgSuyljoOjtmgrErzkgGPETkIbsy4UKFSWgm05oUWPC5c7Uf8hLm9hvL79l6O3PozYz-3Ss1JqVjPSZ_2ccLOe03mf0yxHK3Hv4RP_0f4HTuYZek8n39cXL9ih3Z7mJiE4jUbNPXOvEFc06i33bz9CaUs80c |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ADAMTS-13+Levels+Do+Not+Predict+Outcome+in+Thrombotic+Thrombocytopenic+Purpura%3A+Protein+S+Levels+Are+Maintained+during+Plasma+Exchange+with+Solvent+Detergent+Treated+Plasma&rft.jtitle=Blood&rft.au=Rock%2C+Gail+A.&rft.au=Anderson%2C+David&rft.au=Benny%2C+Barrett&rft.au=Barth%2C+David&rft.date=2007-11-16&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=110&rft.issue=11&rft.spage=2895&rft.epage=2895&rft_id=info:doi/10.1182%2Fblood.V110.11.2895.2895&rft.externalDocID=S0006497119891449 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |